Active — Not RecruitingNot Applicable

Using Transcriptional Assessment of Immune Response to Assess Immunosuppression After Liver Transplantation

United States40 participantsStarted 2023-12-15

Plain-language summary

To develop a prospective quantitative liver allograft monitoring protocol and retrospectively validate the use of Phenotypic personalized medicine (PPM) in immunosuppression dosing in liver transplant recipients.

Who can participate

Age range18 Years – 90 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * At least 18 years of age * At least one-month post-transplant * Recipient of a liver transplant alone or a simultaneous liver-kidney transplant Exclusion Criteria: * Unwilling to provide informed consent * Recipient of a previous bone marrow or stem cell transplant * Pregnant * Unlikely to be able to comply with the study requirements, as determined by the PI

What they're measuring

Episodes of rejection

Timeframe: 6 months

Trial details

NCT IDNCT06063213

SponsorUniversity of Florida

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-10-15

View on ClinicalTrials.gov More Transplant Complication trials